Tesamorelin Cost: Branded Egrifta vs Compounded

Tesamorelin has one of the widest price gaps of any peptide on the market — and the gap is the whole story. On one side sits EGRIFTA SV, the FDA-approved branded drug, which is genuinely expensive: a specialty medication that, at list price, runs into the thousands of dollars per month. On the other sits grey-market 'compounded' or 'research' tesamorelin, sold for a fraction of that. The cheap option is tempting, but the price difference is not a deal — it reflects a real difference in regulation, oversight, and what you're actually buying. This piece lays out both, honestly, and explains why insurance almost never closes the gap.

Note on figures: tesamorelin prices move with manufacturer pricing, pharmacy, and the unregulated grey market, so treat the ranges below as current market context, not a fixed quote. Always get an itemized number from the actual pharmacy or clinic before you budget.

Branded EGRIFTA SV: the FDA-approved, expensive option

EGRIFTA SV is the only FDA-approved tesamorelin product, and its approval is narrow: reducing excess abdominal fat in adults with HIV-associated lipodystrophy¹. As a branded specialty drug for a specific indication, it is priced accordingly — at list price, a month's supply commonly runs in the low-to-mid four figures (roughly several thousand dollars), which is typical for a self-injected specialty biologic. For patients who actually have the approved indication, that cost is usually routed through specialty pharmacy and insurance rather than paid in full out of pocket, and the manufacturer runs a patient-support program. The headline, though, is that the branded drug is a true specialty-pharmacy expense, not a wellness-clinic line item.

Compounded and grey-market tesamorelin: cheap, but a different product

Because branded tesamorelin is costly and indication-restricted, almost all off-label use — for general fat loss, 'belly fat' in healthy adults, bodybuilding cuts, or anti-aging — runs on compounded or outright grey-market 'research' tesamorelin instead. This is dramatically cheaper, often a small fraction of the branded price per month. But you are not buying the same thing. Compounded peptides are not FDA-approved finished drugs; their potency, purity, and sterility depend entirely on the pharmacy or supplier, and 'research-only' vials sold online sit outside the prescription system altogether, with no guarantee the vial contains what the label claims. The low price is real — and so is the trade-off in oversight.

This is the same structural dynamic that drives compounded sermorelin and the other GH peptides: when a branded product is expensive or discontinued, a compounded market fills the gap at a lower price but a lower assurance level. We walk through that pricing logic for the most common GHRH peptide in sermorelin cost: what you'll actually pay.

Why insurance almost never helps off-label

Insurance coverage for tesamorelin follows the indication. If you have HIV-associated lipodystrophy — the one FDA-approved use — branded EGRIFTA SV can be covered through specialty pharmacy with prior authorization, because there is an approved diagnosis to attach it to¹. Outside that, coverage essentially vanishes. General weight loss, body recomposition, and anti-aging are off-label, and the label itself states tesamorelin is not indicated for weight-loss management¹ — so there is no approved diagnosis for an insurer to reimburse against. That is why off-label users end up paying cash, and why the cheap compounded route exists at all. The same wall applies across this drug class; we cover the mechanics in does insurance cover sermorelin?.

Putting cost next to evidence

The honest way to read tesamorelin's price is to set it against what the evidence actually supports. Tesamorelin is the best-validated GHRH analog: Phase III trials show it reduces visceral fat by roughly 15–18% and cuts liver fat in people with HIV-associated lipodystrophy²³, and a systematic review places that visceral-fat efficacy on solid ground⁴. But every one of those results comes from its approved population, the benefit reverses when you stop dosing³, and there is no Phase III evidence that tesamorelin produces meaningful fat loss in healthy, non-HIV adults — the exact people the cheap compounded market sells to. So the cost math is uncomfortable: the expensive branded drug has the evidence but only for a narrow group, while the cheap grey-market version is being used for the very indications where the evidence is thinnest. Paying less for an unproven, unregulated use is not the bargain it looks like. For the full accounting of what tesamorelin is and isn't proven to do, see tesamorelin benefits: what the evidence shows.

The bottom line

Tesamorelin's cost splits cleanly in two. Branded EGRIFTA SV is an FDA-approved specialty drug that runs into the thousands per month at list price, is usually accessed through specialty pharmacy and insurance, and is realistically reimbursed only for its one approved indication — HIV-associated lipodystrophy¹. Grey-market or compounded tesamorelin is far cheaper, which is why nearly all off-label use runs on it, but the savings come from skipping the regulation, oversight, and quality guarantees that make the branded drug expensive. Insurance rarely bridges the gap because off-label use has no approved diagnosis to bill against. And the most important caveat is the evidence one: the proven benefits live in the expensive, narrowly indicated lane, not the cheap, off-label one. For the broader GH-peptide cost and access landscape, start with our pillar guide, Sermorelin for Sleep, Recovery & Healthy Aging, and if you're weighing providers and prices, we rank them in our guide to the best sermorelin providers.